At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 61 target
Drug / intervention
IMP9064drug
Likely dose
Not stated in record
Key inclusion· 5
- ✓Advanced solid tumor refractory to or intolerant of standard-of-care therapy or for which no standard treatment exists
- ✓Age 18 years or older at screening
- ✓Provision of tumor tissue samples
- ✓Life expectancy at least 12 weeks
Key exclusion· 17
- ✕Known hypersensitivity to study drug components
- ✕Primary CNS tumor or active/untreated CNS metastases
- ✕Uncontrolled acute infection or active infection requiring systemic treatment within 14 days
- ✕Known active hepatitis B or C infection
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation and Dose-expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of the ATR Inhibitor IMP9064 Monotherapy and in Combination With PARP Inhibitor Senaparib in Patients With Advanced Solid Tumors
In Brief
A Phase 2 clinical trial evaluating IMP9064 for Solid Tumor and Advanced Solid Tumor. Currently recruiting, targeting 61 participants across 8 sites in 4 countries.
Detailed Summary
This is a Phase 1/2, multicenter, open-label study to evaluate the safety and efficacy of IMP9064 as monotherapy or in combination with PARP inhibitor Senaparib in patients with advanced solid tumors
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSolid Tumor, Advanced Solid Tumor
CountriesAustralia, China, Taiwan, United States
Collaborators--
Timeline
Phase 2Recruiting
202220232024202520262027
Enrollment StartFeb 2022
First PostedMar 2022
TodayJul 2026
Primary CompletionDec 2026
First PostedMar 7, 2022
Enrollment StartFeb 11, 2022
Primary CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 4.9 yearsPosted 4.3 years agoPrimary completion in 6 months
Interventions
IMP9064drug
IMP9064 Monotherapy administered for 21 days